Cargando…

Correction: Reactivation of low avidity tumor-specific CD8+ T cells associates with immunotherapeutic efficacy of anti-PD-1

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462973/ https://www.ncbi.nlm.nih.gov/pubmed/37640481 http://dx.doi.org/10.1136/jitc-2023-007114corr1

Ejemplares similares

Reactivation of low avidity tumor-specific CD8(+) T cells associates with immunotherapeutic efficacy of anti-PD-1
por: Sugiyarto, Gessa, et al.
Publicado: (2023)

Correction: Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy
por: Fumet, Jean-David, et al.
Publicado: (2019)

Correction: Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds
Publicado: (2021)

Correction: CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment
Publicado: (2022)

Correction: GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors
Publicado: (2021)

Protective low-avidity anti-tumour CD8+ T cells are selectively attenuated by regulatory T cells
por: Sugiyarto, Gessa, et al.
Publicado: (2020)

Combinatorial immunotherapeutic approaches to restore the function of anergic tumor-reactive cytotoxic CD8(+) T cells
por: Redmond, William L., et al.
Publicado: (2016)

Correction to: Aspinall S, et al. Human Vaccines and Immunotherapeutics Volume 8, Issue 8; pp.1109–18
por: Aspinall, Sanet, et al.
Publicado: (2013)

Correction: Impact of CD4 T cells on intratumoral CD8 T-cell exhaustion and responsiveness to PD-1 blockade therapy in mouse brain tumors
Publicado: (2023)

Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors
por: Schmidt, Julien, et al.
Publicado: (2023)

Correction: CD40 Activation Rescues Antiviral CD8(+) T Cells from PD-1-Mediated Exhaustion
por: Isogawa, Masanori, et al.
Publicado: (2016)

Correction: CD40 Activation Rescues Antiviral CD8(+) T Cells from PD-1-Mediated Exhaustion
por: Isogawa, Masanori, et al.
Publicado: (2017)

Correction: The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow
por: Lange, Andrzej, et al.
Publicado: (2018)

SECTM1 is upregulated in immuno-hot tumors and predicts immunotherapeutic efficacy in multiple cancers
por: Mei, Jie, et al.
Publicado: (2023)

Proinsulin Expression Shapes the TCR Repertoire but Fails to Control the Development of Low-Avidity Insulin-Reactive CD8(+) T Cells
por: Pearson, James A., et al.
Publicado: (2016)

Correction: CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy
Publicado: (2022)

Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent
por: Wang, Pengju, et al.
Publicado: (2018)

Author Correction: Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo
por: Li, Maohua, et al.
Publicado: (2022)

Correction: Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer
Publicado: (2021)

Correction: How Does Cross-Reactive Stimulation Affect the Longevity of CD8+ T Cell Memory?
por: Ganusov, Vitaly V, et al.
Publicado: (2006)

Author Correction: CD8+T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomas
por: Niborski, Leticia Laura, et al.
Publicado: (2023)

Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
por: Reusing, Sarah B., et al.
Publicado: (2021)

Role of functional avidity in HIV-specific memory CD8 T cell effector functions
por: Lemon, Tiffany, et al.
Publicado: (2012)

Correction: Depletion of Regulatory T Cells Induces High Numbers of Dendritic Cells and Unmasks a Subset of Anti-Tumour CD8(+)CD11c(+) PD-1(lo) Effector T Cells
por: Goudin, Nicolas, et al.
Publicado: (2017)

Author Correction: Tumor-specific memory CD8(+) T cells are strictly resident in draining lymph nodes during tumorigenesis
por: Liu, Qiao, et al.
Publicado: (2023)

Correction: Co-Infection with Mycobacterium tuberculosis Impairs HIV-Specific CD8+ and CD4+ T Cell Functionality
Publicado: (2015)

Correction: Ultrasound combined with nanobubbles promotes systemic anticancer immunity and augments anti-PD1 efficacy
Publicado: (2022)

Correction: Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer
por: Jia, Keren, et al.
Publicado: (2023)

Publisher Correction: Pharmacological reactivation of MYC-dependent apoptosis induces susceptibility to anti-PD-1 immunotherapy
por: Haikala, Heidi M., et al.
Publicado: (2019)

Immunotherapeutic potential of CD4 and CD8 single-positive T cells in thymic epithelial tumors
por: Yamamoto, Yoko, et al.
Publicado: (2020)

Author Correction: Liposomal delivery of azithromycin enhances its immunotherapeutic efficacy and reduces toxicity in myocardial infarction
por: Al‑Darraji, Ahmed, et al.
Publicado: (2021)

Correction to: persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1
por: Smith, Kellie N., et al.
Publicado: (2019)

Correction: PD-L1 Expression on Retrovirus-Infected Cells Mediates Immune Escape from CD8+ T Cell Killing
por: Akhmetzyanova, Ilseyar, et al.
Publicado: (2015)

Correction to: Tcf‑1 protects anti‑tumor TCR‑engineered CD8(+) T‑cells from GzmB mediated self‑destruction
por: Zangari, Brendan, et al.
Publicado: (2022)

Elderly CD8(+) T cells in the focus for immunotherapeutic approaches
por: Lis, Annette, et al.
Publicado: (2023)

Correction: Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors
por: Pires, Eusebio S., et al.
Publicado: (2017)

Glu227-->Lys substitution in the acidic loop of major histocompatibility complex class I alpha 3 domain distinguishes low avidity CD8 coreceptor and avidity-enhanced CD8 accessory functions
Publicado: (1996)

Correction: Expression Patterns of Bovine CD1 In Vivo and Assessment of the Specificities of the Anti-Bovine CD1 Antibodies
Publicado: (2015)

Correction to: Repeated SARS-CoV-2 vaccination in cancer patients treated with immune checkpoint inhibitors: induction of high-avidity anti-RBD neutralizing antibodies
por: Caruso, Teresita, et al.
Publicado: (2023)

Correction: Protein-based prognostic signature for predicting the survival and immunotherapeutic efficiency of endometrial carcinoma
por: Lai, Jinzhi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ttcstl6gr7t7md91nohi4ndn2e